Matthew Pando, John Jaskowiak, Philippe Rousseau, Bruno Tocque, Douglas Amorese | GenomeWeb
ExonHit Therapeutics said last week that Matthew Pando and John Jaskowiak will join the company’s management board, and Philippe Rousseau will become president of the board until the company appoints a new CEO. Rousseau has been chief financial officer at ExonHit since 2002 and has been a member of its management board since 2004. The firm’s previous CEO and co-founder Bruno Tocque will remain with ExonHit in a consulting position.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.